Investor News: Lawsuit against OHR Pharmaceutical Inc (NASDAQ:OHRP) filed

An investor, who purchased shares of OHR Pharmaceutical Inc (NASDAQ:OHRP), filed a lawsuit over alleged violations of Federal Securities Laws by OHR Pharmaceutical Inc.

Investors who purchased shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) have certain options and for certain investors are short and strict deadlines running. Deadline: April 16, 2018. NASDAQ:OHRP investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

On June 24, 2014, OHR Pharmaceutical Inc announced positive top-line interim results for its double-masked, placebo-controlled Phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (wet AMD).

On January 05, 2018, Ohr Pharmaceutical, Inc. reported topline data from the MAKO study which did not meet its primary efficacy endpoint. The MAKO study evaluated the efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet age-related macular degeneration (“wet-AMD”). Shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) declined from $2.18 per share on January 3, 2018 to as low as $0.35 per share on January 5, 2018.

According to the complaint the plaintiff alleges on behalf of purchasers of OHR Pharmaceutical Inc (NASDAQ:OHRP) common shares between June 24, 2014 and January 4, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 24, 2014 and January 4, 2018, the defendants made false and/or misleading statements and/or failed to disclose that OHR Pharmaceutical Inc’s lead product Squalamine would not produce vision improvements and was commercially not viable, and that as a result of the foregoing, Defendants’ statements about OHR Pharmaceutical Inc’s business, operations, and prospects were misleading and/or lacked a reasonable basis.

Those who purchased shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com